IT 139

Drug Profile

IT 139

Alternative Names: IT-139; KP-1339; NKP-1339

Latest Information Update: 22 Jun 2017

Price : $50

At a glance

  • Originator University of Vienna
  • Developer Intezyne
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Apoptosis stimulants; DNA inhibitors; JNK mitogen-activated protein kinase inhibitors; Molecular chaperone GRP78 protein inhibitors; P38 mitogen-activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 20 Jun 2017 IT 139 receives Orphan Drug status for Pancreatic cancer in USA
  • 16 Apr 2016 Adverse event and efficacy data from a phase I trial in Solid tumours presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016) (3180896; 3182100)
  • 16 Apr 2016 Pharmacodynamics data from a preclinical study in Solid tumours presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top